IP Library Granted Patent US 8,932,576
Granted Patent B2
US 8,932,576 · App. 12/695,101 · Granted Jan 13, 2015

Robust expression of a bioactive mammalian protein in

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,932,576
App. No.
12/695,101
Granted
Jan 13, 2015
Kind
B2
Abstract

Methods and compositions are disclosed to engineer chloroplast comprising heterologous mammalian genes via a direct replacement of chloroplast Photosystem II (PSII) reaction center protein coding regions to achieve expression of recombinant protein above 5% of total protein. When algae is used, algal expressed protein is produced predominantly as a soluble protein where the functional activity of the peptide is intact. As the host algae is edible, production of biologics in this organism for oral delivery of proteins/peptides, especially gut active proteins, without purification is disclosed.

Claims (8)

1. A method of treating intestinal bacterial or viral infection comprising administering to a subject in need thereof a therapeutically effective amount of an alga obtained from an algal cell transformed by replacing an endogenous chloroplast gene via integration of a chimeric construct having a heterologous coding sequence, a promoter sequence, at least one UTR, and nucleotide sequences of chloroplast genomic DNA flanking the heterologous coding sequence, the promoter sequence and the at least one UTR, the nucleotide sequences operable to allow homologous recombination of the construct with the chloroplast genome and replacement of the endogenous chloroplast gene, wherein the endogenous chloroplast gene is re-inserted at a silent distal site, wherein the promoter is cognate or non-cognate to the endogenous chloroplast gene, and wherein the heterologous coding sequence encodes a protein useful for treating the intestinal bacterial or viral infection.

2. The method of claim 1 , wherein the alga is administered prophylactically.

3. The method of claim 1 , wherein the alga comprises a peptide as set forth in SEQ ID NO:2.

4. The method of claim 1 , wherein the bacterial infection results from exposure to an enteropathogenic Escherichia coli.

5. The method of claim 4 , wherein the bacterial infection is necrotizing enterocolitis or infectious diarrhea.

6. The method of claim 1 , wherein the subject is a newborn or an infant.

7. The method of claim 1 , wherein the subject is a mammal.

8. The method of claim 7 , wherein the subject is human, bovine, or porcine.

Assignments (5)
CONFIRMATORY LICENSE Recorded Dec 21, 2017
From: SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044939/0050 →
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL AT REEL/FRAME NO. 30157/0052 Recorded Dec 15, 2015
From: THE WELLCOME TRUST LIMITED
To: SAPPHIRE ENERGY, INC.
Reel/Frame 037300/0279 →
SECURITY AGREEMENT Recorded Apr 5, 2013
From: SAPPHIRE ENERGY, INC.
To: THE WELLCOME TRUST LIMITED
Reel/Frame 030157/0052 →
CONFIRMATORY LICENSE Recorded Feb 15, 2011
From: SCRIPPS RESEARCH INSTITUTE, THE
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 025799/0888 →
CONFIRMATORY LICENSE Recorded Apr 7, 2010
From: THE SCRIPPS RESEARCH INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024198/0785 →